Compare Organon & Co. Common Stock (OGN) vs SentinelOne Inc. Class A Common Stock (S) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs SentinelOne Inc. Class A Common Stock — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while SentinelOne Inc. Class A Common Stock trades at $22.64 (market cap $8.36B). The key difference: SentinelOne Inc. Class A Common Stock is far larger — about 2.3× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while SentinelOne Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and SentinelOne Inc. Class A Common Stock for 6 Days on average.
| OGN | S | |
|---|---|---|
Market Cap | $3.62B | $8.36B |
Volume | 2,892,999 | 27,558,313 |
Sector | Health | Technology |
52-Week High | $13.81 | $26.27 |
52-Week Low | $5.70 | $11.94 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $11.04B | $7.74B |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
SentinelOne (S) trades at $24.01, down 6.43% amid news of a $1.25 billion convertible notes offering. The stock shows bullish technical signals with strong moving average support, though oscillators remain neutral. Fundamentally, the company maintains robust revenue growth (21% YoY) and high gross margins (72.54%) but continues to report significant net losses (-$288M in 2025). Recent analyst recognition as a leader in endpoint security and expanding cloud capabilities provide positive business momentum.
Investment outlook balances strong growth potential against persistent profitability challenges. The convertible notes offering signals aggressive expansion but increases financial leverage. With 65% analyst buy ratings and a $23.42 consensus target, Wall Street remains optimistic about long-term cybersecurity demand, though investors face execution risk and competitive pressures in a capital-intensive growth phase.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About SentinelOne Inc. Class A Common Stock
SentinelOne provides an AI-powered cybersecurity platform for organizations. Its Singularity platform helps detect, prevent, and respond to threats across endpoints, cloud workloads, identities, and connected devices.
Read more on S →
